We report the long-term efficacy and safety from the multicenter, randomized, double-blind, placebo-controlled, phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 (NCT03522246) study of first-line rucaparib maintenance for advanced ovarian cancer.
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study☆
Annals of Oncology | | R.S. Kristeleit, S. Ghamande, A. Lisyanskaya, A. Oaknin, E. Prendergast, Y.B. Kim, J. Fuentes Pradera, R.D. Littell, B. Gao, G. Valabrega, D.M. O’Malley, A. Dean, C. Pisano, J. Buscema, D. Provencher, F. Zagouri, L.P. Martin, H.-H. Chou, F. Demirkiran, F. Ueland, A. Chudecka-Głaz, O. Yeku, M. Beiner, C. Anderson, V. Drochytek, R.N. Eskander, R. Agarwal, L. Maloney, D. Despain, C. Connor, M. Craib, D. Shih, K. Fujiwara, B.J. Monk
Topics: blood-cancer, ovarian-cancer, clinical-trials, research